116 related articles for article (PubMed ID: 11875370)
1. Pharmacological properties of the naturally occurring Ala(457)Pro variant of the human norepinephrine transporter.
Paczkowski FA; Bönisch H; Bryan-Lluka LJ
Pharmacogenetics; 2002 Mar; 12(2):165-73. PubMed ID: 11875370
[TBL] [Abstract][Full Text] [Related]
2. Tyrosine residue 271 of the norepinephrine transporter is an important determinant of its pharmacology.
Paczkowski FA; Bryan-Lluka LJ
Brain Res Mol Brain Res; 2001 Dec; 97(1):32-42. PubMed ID: 11744160
[TBL] [Abstract][Full Text] [Related]
3. Functional importance of the C-terminus of the human norepinephrine transporter.
Distelmaier F; Wiedemann P; Brüss M; Bönisch H
J Neurochem; 2004 Nov; 91(3):537-46. PubMed ID: 15485485
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological properties of naturally occurring variants of the human norepinephrine transporter.
Runkel F; Brüss M; Nöthen MM; Stöber G; Propping P; Bönisch H
Pharmacogenetics; 2000 Jul; 10(5):397-405. PubMed ID: 10898109
[TBL] [Abstract][Full Text] [Related]
5. Amino acids involved in differences in the pharmacological profiles of the rat and human noradrenaline transporters.
Paczkowski FA; Bryan-Lluka LJ
Naunyn Schmiedebergs Arch Pharmacol; 2002 Apr; 365(4):312-7. PubMed ID: 11919656
[TBL] [Abstract][Full Text] [Related]
6. The role of the conserved GXXXRXG motif in the expression and function of the human norepinephrine transporter.
Sucic S; Bryan-Lluka LJ
Brain Res Mol Brain Res; 2002 Dec; 108(1-2):40-50. PubMed ID: 12480177
[TBL] [Abstract][Full Text] [Related]
7. Down-regulation of the human norepinephrine transporter in intact 293-hNET cells exposed to desipramine.
Zhu MY; Blakely RD; Apparsundaram S; Ordway GA
J Neurochem; 1998 Apr; 70(4):1547-55. PubMed ID: 9523572
[TBL] [Abstract][Full Text] [Related]
8. Functional characterization of the splicing variants of human norepinephrine transporter.
Kitayama S; Morita K; Dohi T
Neurosci Lett; 2001 Oct; 312(2):108-12. PubMed ID: 11595346
[TBL] [Abstract][Full Text] [Related]
9. Voltammetric studies on mechanisms of dopamine efflux in the presence of substrates and cocaine from cells expressing human norepinephrine transporter.
Chen N; Trowbridge CG; Justice JB
J Neurochem; 1998 Aug; 71(2):653-65. PubMed ID: 9681456
[TBL] [Abstract][Full Text] [Related]
10. Mutations of tyrosine 467 in the human norepinephrine transporter attenuate HIV-1 Tat-induced inhibition of dopamine transport while retaining physiological function.
Strauss MJ; Porter KD; Quizon PM; Davis SE; Lin S; Yuan Y; Martinez-Muniz GA; Sun WL; Zhan CG; Zhu J
PLoS One; 2022; 17(9):e0275182. PubMed ID: 36170295
[TBL] [Abstract][Full Text] [Related]
11. A mutation in the human norepinephrine transporter gene (SLC6A2) associated with orthostatic intolerance disrupts surface expression of mutant and wild-type transporters.
Hahn MK; Robertson D; Blakely RD
J Neurosci; 2003 Jun; 23(11):4470-8. PubMed ID: 12805287
[TBL] [Abstract][Full Text] [Related]
12. Functional significance of a highly conserved glutamate residue of the human noradrenaline transporter.
Sucic S; Paczkowski FA; Runkel F; Bönisch H; Bryan-Lluka LJ
J Neurochem; 2002 Apr; 81(2):344-54. PubMed ID: 12064482
[TBL] [Abstract][Full Text] [Related]
13. Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter: evidence from knock-out mouse lines.
Morón JA; Brockington A; Wise RA; Rocha BA; Hope BT
J Neurosci; 2002 Jan; 22(2):389-95. PubMed ID: 11784783
[TBL] [Abstract][Full Text] [Related]
14. Sodium-dependent norepinephrine-induced currents in norepinephrine-transporter-transfected HEK-293 cells blocked by cocaine and antidepressants.
Galli A; DeFelice LJ; Duke BJ; Moore KR; Blakely RD
J Exp Biol; 1995 Oct; 198(Pt 10):2197-212. PubMed ID: 7500004
[TBL] [Abstract][Full Text] [Related]
15. The persistent membrane retention of desipramine causes lasting inhibition of norepinephrine transporter function.
Zhu MY; Kyle PB; Hume AS; Ordway GA
Neurochem Res; 2004 Feb; 29(2):419-27. PubMed ID: 15002740
[TBL] [Abstract][Full Text] [Related]
16. Desipramine treatment decreases 3H-nisoxetine binding and norepinephrine transporter mRNA in SK-N-SHSY5Y cells.
Zavosh A; Schaefer J; Ferrel A; Figlewicz DP
Brain Res Bull; 1999 Jul; 49(4):291-5. PubMed ID: 10424850
[TBL] [Abstract][Full Text] [Related]
17. Roles of transmembrane domain 2 and the first intracellular loop in human noradrenaline transporter function: pharmacological and SCAM analysis.
Sucic S; Bryan-Lluka LJ
J Neurochem; 2005 Sep; 94(6):1620-30. PubMed ID: 16092934
[TBL] [Abstract][Full Text] [Related]
18. chi-Conopeptide MrIA partially overlaps desipramine and cocaine binding sites on the human norepinephrine transporter.
Bryan-Lluka LJ; Bönisch H; Lewis RJ
J Biol Chem; 2003 Oct; 278(41):40324-9. PubMed ID: 12837768
[TBL] [Abstract][Full Text] [Related]
19. Inability to N-glycosylate the human norepinephrine transporter reduces protein stability, surface trafficking, and transport activity but not ligand recognition.
Melikian HE; Ramamoorthy S; Tate CG; Blakely RD
Mol Pharmacol; 1996 Aug; 50(2):266-76. PubMed ID: 8700133
[TBL] [Abstract][Full Text] [Related]
20. Norepinephrine transporter immunoblotting and radioligand binding in cocaine abusers.
Mash DC; Ouyang Q; Qin Y; Pablo J
J Neurosci Methods; 2005 Apr; 143(1):79-85. PubMed ID: 15763139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
